UCB-MNCs
Phase 1Biologic
UCB-MNCs is one of 7 biologic programs targeting Enteritis. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
9 competitors in Enteritis
#DrugCompanyPhaseTrials
1Qvar
SSchering-Plough
Approved
Entyvio
TakedaPhase 2
Tetrahydrobiopterin
OOrphanetics Pharma Entwicklungs GmbH
Phase 2
Emapalumab
SSwedish Orphan Biovitrum
Phase 2
OPS-2071
OtsukaPhase 2
Glutamine
SanofiPreclinical
UCB-MNCs
ZZhejiang Cancer Hospital
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for UCB-MNCs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- ZZhejiang Cancer Hospital